Preparing for Increased Use With millions of patients taking GLP-1 medications, including semaglutide, tirzepatide, liraglutide, and dulaglutide, dental teams will encounter these therapies more frequently in practice
Interventional studies are in fact limited by issues of bioavailability and metabolism
These include potential heart disease, kidney damage and nerve issues
Here is why: CJC-1295 acts as a GHRH analog, telling the pituitary to produce more GH Ipamorelin is a growth hormone secretagogue that stimulates GH release through the ghrelin receptor pathway Together, they amplify GH output through two complementary mechanisms Pharmacology studies describe how GHRH analogs and growth hormonereleasing peptides act on the GH/IGF-I axis to support growth hormone output (Veldhuis et al., 2009)
Clinical trials, including the SURMOUNT-5 study, demonstrate tirzepatides ability to achieve 13.7-20.2% weight loss in individuals with obesity but without type 2 diabetes, outperforming other GLP-1 receptor agonists in direct comparisons
These improvements likely result from reduced lymphatic load, decreased inflammatory mediators, and enhanced lymphatic vessel function
